FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1991657560> ?p ?o ?g. }

• W1991657560 endingPage "398" @default.
• W1991657560 startingPage "390" @default.
• W1991657560 abstract "Previous studies of the glycoprotein IIb-IIIa inhibitor eptifibatide have included patients with moderate renal impairment (serum creatinine concentrations, 2.0-4.0 mg/dL). In these patients, adjustment of the standard infusion dose (2.0 microg/kg.min) to 1.0 microg/kg.min was recommended on empiric grounds because approximately 50% of eptifibatide is cleared renally.The present study was designed to assess teh pharmacokinetic and pharmacodynamic properties of eptifibatide in subjects with various levels of creatinine clearance (CrCl), a parameter that is a more accurate indicator of renal function than serum creatinine concentration to determine the appropriate dose adjustment in patients with reduced renal function. A secondary objective was to determine the tolerability of eptifibatide when administered to patients with decreased renal function.This open-label study was concluded at 3 US sites experienced in conducting similar studies. Subjects with differing renal function (normal [group 1, CrCl > 80 mL/min], mild renal impairment [group 2, CrCl 51-80 mL/min], moderate renal impairment [group 3, CrCl 30-50 mL/min], or severe renal impairment [group 4, CrCl <30 mL/min]) received a 24-hour eptifibatide infusion of 2.0 microg/kg.min (groups 1, 2, and 3) or 1.0 microg/kg.min (group 4). The primary end point was the eptifibatide steady-state plasma concentration; the secondary end points included inhibition of platelet aggregation and eptifibatide clearance, terminal plasma half-life, and area under the plasma concentration-time curve. In addition to analyses performed for each group, pharmacokinetic models were estimated and eptifibatide clearance was related to CrCl as a continuous variable by linear regression. All adverse events were recorded, with particular attention to bleeding.Thirty-one subjects (21 men, 10 women; mean age, 58.5 years [range, 44-73 years]; mean body weight, 81.6 kg [range, 51.5-105.1 kg]; mean height, 162.9 cm [range, 150-183 cm]) were included in the study. A strong correlation was found between eptifibatide clearance and CrCl. A tree-based analytic model indicated that the optimal discrete break point for the purpose of dose adjustment was a CrCl of 55.85 mL/min, which was rounded to 50 mL/min for practical clinical reasons. In patients with moderate or severe renal impairment (CrCl < or = 50 mL/min), clearance rates and steady-state concentrations of eptifibatide were approximately 50% lower and almost 2-fold higher, respectively, than in patients with normal renal function or mild renal impairment (CrCl > 50 mL/min). Inhibition of platelet aggregation exceeded the clinically significant threshold of 80% in all groups. Five subjects had a mild bleeding event and 4 subjects experienced mild to moderate nonbleeding events, 2 of which were considered drug-related by the investigator. None of the events required intervention.In this study, moderate to severe renal impairment was associated with an approximately 50% reduction in total eptifibatide clearance and a corresponding doubling of plasma eptifibatide concentration. Based on these findings, in patients with moderately or severely impaired renal function (calculated CrCl < or =50 mL/min) who are scheduled for percutaneous coronary intervention or who have non-ST-segment elevation acute coronary syndromes, it is appropriate to reduce the infusion dose of eptifibatide by 50% (from 2 to 1 microg/kg.min). Because the bolus dose(s) is (are) used to establish the initial targeted plasma eptifibatide concentrations, which are independent of clearance, and given that the volume of distribution did not correlate with renal function, no adjustment of the bolus dose(s) is required." @default.
• W1991657560 created "2016-06-24" @default.
• W1991657560 creator A5015018500 @default.
• W1991657560 creator A5033161439 @default.
• W1991657560 creator A5085197690 @default.
• W1991657560 date "2004-01-01" @default.
• W1991657560 modified "2023-09-27" @default.
• W1991657560 title "Pharmacokinetic and pharmacodynamic properties of eptifibatide in subjects with normal or impaired renal function" @default.
• W1991657560 cites W1550111394 @default.
• W1991657560 cites W182370232 @default.
• W1991657560 cites W2037465103 @default.
• W1991657560 cites W2108484910 @default.
• W1991657560 cites W2120309051 @default.
• W1991657560 cites W2168079615 @default.
• W1991657560 cites W2168494093 @default.
• W1991657560 cites W4254730674 @default.
• W1991657560 cites W4256202725 @default.
• W1991657560 doi "https://doi.org/10.1016/s0149-2918(04)90034-3" @default.
• W1991657560 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15110131" @default.
• W1991657560 hasPublicationYear "2004" @default.
• W1991657560 type Work @default.
• W1991657560 sameAs 1991657560 @default.
• W1991657560 citedByCount "36" @default.
• W1991657560 countsByYear W19916575602012 @default.
• W1991657560 countsByYear W19916575602015 @default.
• W1991657560 countsByYear W19916575602017 @default.
• W1991657560 countsByYear W19916575602018 @default.
• W1991657560 countsByYear W19916575602019 @default.
• W1991657560 countsByYear W19916575602020 @default.
• W1991657560 countsByYear W19916575602021 @default.
• W1991657560 crossrefType "journal-article" @default.
• W1991657560 hasAuthorship W1991657560A5015018500 @default.
• W1991657560 hasAuthorship W1991657560A5033161439 @default.
• W1991657560 hasAuthorship W1991657560A5085197690 @default.
• W1991657560 hasConcept C111113717 @default.
• W1991657560 hasConcept C112705442 @default.
• W1991657560 hasConcept C126322002 @default.
• W1991657560 hasConcept C126894567 @default.
• W1991657560 hasConcept C159641895 @default.
• W1991657560 hasConcept C2780306776 @default.
• W1991657560 hasConcept C2781056559 @default.
• W1991657560 hasConcept C45393284 @default.
• W1991657560 hasConcept C500558357 @default.
• W1991657560 hasConcept C71924100 @default.
• W1991657560 hasConcept C98274493 @default.
• W1991657560 hasConceptScore W1991657560C111113717 @default.
• W1991657560 hasConceptScore W1991657560C112705442 @default.
• W1991657560 hasConceptScore W1991657560C126322002 @default.
• W1991657560 hasConceptScore W1991657560C126894567 @default.
• W1991657560 hasConceptScore W1991657560C159641895 @default.
• W1991657560 hasConceptScore W1991657560C2780306776 @default.
• W1991657560 hasConceptScore W1991657560C2781056559 @default.
• W1991657560 hasConceptScore W1991657560C45393284 @default.
• W1991657560 hasConceptScore W1991657560C500558357 @default.
• W1991657560 hasConceptScore W1991657560C71924100 @default.
• W1991657560 hasConceptScore W1991657560C98274493 @default.
• W1991657560 hasIssue "3" @default.
• W1991657560 hasLocation W19916575601 @default.
• W1991657560 hasLocation W19916575602 @default.
• W1991657560 hasOpenAccess W1991657560 @default.
• W1991657560 hasPrimaryLocation W19916575601 @default.
• W1991657560 hasRelatedWork W1544023406 @default.
• W1991657560 hasRelatedWork W1830795151 @default.
• W1991657560 hasRelatedWork W1973741567 @default.
• W1991657560 hasRelatedWork W1974378936 @default.
• W1991657560 hasRelatedWork W2014603468 @default.
• W1991657560 hasRelatedWork W2046899919 @default.
• W1991657560 hasRelatedWork W2227061539 @default.
• W1991657560 hasRelatedWork W3117263584 @default.
• W1991657560 hasRelatedWork W393698729 @default.
• W1991657560 hasRelatedWork W4296385806 @default.
• W1991657560 hasVolume "26" @default.
• W1991657560 isParatext "false" @default.
• W1991657560 isRetracted "false" @default.
• W1991657560 magId "1991657560" @default.
• W1991657560 workType "article" @default.